## Jason L Eriksen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7922795/publications.pdf

Version: 2024-02-01

67 12,835 32 61 g-index

79 79 79 21238

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	27.8	1,816
3	A subset of NSAIDs lower amyloidogenic $\hat{Al^2}$ 42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216.	27.8	1,352
4	AÎ <sup>2</sup> 42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron, 2005, 47, 191-199.	8.1	524
5	NSAIDs and enantiomers of flurbiprofen target $\hat{I}^3$ -secretase and lower A $\hat{I}^2$ 42 in vivo. Journal of Clinical Investigation, 2003, 112, 440-449.	8.2	476
6	Substrate-targeting $\hat{I}^3$ -secretase modulators. Nature, 2008, 453, 925-929.	27.8	277
7	Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production. Nature Medicine, 2005, 11, 545-550.	30.7	276
8	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	2.9	271
9	A decade of modeling Alzheimer's disease in transgenic mice. Trends in Genetics, 2006, 22, 281-289.	6.7	266
10	Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid $\hat{l}^2$ 42 Production by Direct Modulation of $\hat{l}^3$ -Secretase Activity. Journal of Biological Chemistry, 2003, 278, 31831-31837.	3.4	259
11	Molecular Pathogenesis of Parkinson Disease. Archives of Neurology, 2005, 62, 353.	4.5	236
12	NSAIDs and enantiomers of flurbiprofen target $\hat{I}^3$ -secretase and lower A $\hat{I}^2$ 42 in vivo. Journal of Clinical Investigation, 2003, 112, 440-449.	8.2	214
13	An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9673-9678.	7.1	206
14	Caught in the Act. Neuron, 2003, 40, 453-456.	8.1	184
15	Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration. Behavior Genetics, 2007, 37, 79-100.	2.1	130
16	$\hat{Al^2}$ 42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain. Journal of Biological Chemistry, 2003, 278, 30748-30754.	3.4	119
17	Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neuroscience, 2007, 8, 54.	1.9	118
18	Progranulin: normal function and role in neurodegeneration. Journal of Neurochemistry, 2008, 104, 287-297.	3.9	114

#	Article	IF	Citations
19	NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. Trends in Pharmacological Sciences, 2007, 28, 536-543.	8.7	113
20	Gene dosage and pathogenesis of Parkinson's disease. Trends in Molecular Medicine, 2005, 11, 91-96.	6.7	95
21	Treadmill Exercise Prevents Learning and Memory Impairment in Alzheimer's Disease-Like Pathology. Current Alzheimer Research, 2013, 10, 507-515.	1.4	83
22	Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors. Current Alzheimer Research, 2005, 2, 231-238.	1.4	77
23	Inhibitory Neuron and Hippocampal Circuit Dysfunction in an Aged Mouse Model of Alzheimer's Disease. PLoS ONE, 2013, 8, e64318.	2.5	73
24	Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Molecular Neurodegeneration, 2014, 9, 54.	10.8	72
25	The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid κ42 Production. Journal of Biological Chemistry, 2003, 278, 31825-31830.	3.4	71
26	Intravenous Delivery of Targeted Liposomes to Amyloid- $\hat{l}^2$ Pathology in APP/PSEN1 Transgenic Mice. PLoS ONE, 2012, 7, e48515.	2.5	56
27	$\hat{l}^2$ <sub>2</sub> -Adrenoceptor Agonists Are Required for Development of the Asthma Phenotype in a Murine Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 220-229.	2.9	53
28	Effects of ethanol and 5-HT1A agonists on astroglial S100B. Developmental Brain Research, 2002, 139, 97-105.	1.7	47
29	The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related Proteins. Journal of Biological Chemistry, 2013, 288, 1114-1124.	3.4	47
30	A novel function for pro <scp>SAAS</scp> as an amyloid antiâ€aggregant in Alzheimer's disease. Journal of Neurochemistry, 2014, 128, 419-430.	3.9	44
31	Astrocyte-mediated trophic support of developing serotonin neurons: effects of ethanol, buspirone, and S100B. Developmental Brain Research, 2001, 131, 9-15.	1.7	38
32	Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 1029-1034.	3.2	35
33	Cysteine based novel noncompetitive inhibitors of urease(s)—Distinctive inhibition susceptibility of microbial and plant ureases. Bioorganic and Medicinal Chemistry, 2006, 14, 6737-6744.	3.0	34
34	Effects of in utero ethanol exposure and maternal treatment with a 5-HT1A agonist on \$100B-containing glial cells. Developmental Brain Research, 2000, 121, 133-143.	1.7	33
35	Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease. International Journal of Neuropsychopharmacology, 2014, 17, 593-602.	2.1	32
36	A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2016, 52, 731-745.	2.6	31

#	Article	IF	Citations
37	Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes. Developmental Brain Research, 2001, 128, 157-164.	1.7	22
38	Aging Is Not Associated with Proteasome Impairment in UPS Reporter Mice. PLoS ONE, 2009, 4, e5888.	2.5	22
39	Editorial [Hot Topic: The Complex and Multifactorial Nature of Alzheimers Disease (Guest Editors:) Tj ETQq1 1 0.	784314 rg	BT_lOverlock
40	Chronic treatment with DCPCX, an adenosine A1 antagonist, worsens long-term memory. Neuroscience Letters, 2013, 548, 296-300.	2.1	22
41	Plasmonic nanoparticle-based expansion microscopy with surface-enhanced Raman and dark-field spectroscopic imaging. Biomedical Optics Express, 2018, 9, 603.	2.9	17
42	Three-Dimensional Microscopy by Milling with Ultraviolet Excitation. Scientific Reports, 2019, 9, 14578.	3.3	17
43	Effects of Maternal Ethanol Consumption and Buspirone Treatment on Dopamine and Norepinephrine Reuptake Sites and D1 Receptors in Offspring. Alcoholism: Clinical and Experimental Research, 1997, 21, 452-459.	2.4	14
44	Recent Insights into the Involvement of Progranulin in Frontotemporal Dementia. Current Neuropharmacology, 2011, 9, 632-642.	2.9	13
45	Exercise training ameliorates cerebrovascular dysfunction in a murine model of Alzheimer's disease: role of the P2Y2 receptor and endoplasmic reticulum stress. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1559-H1569.	3.2	13
46	Altering the Substrate Specificity of Rhll by Directed Evolution. ChemBioChem, 2009, 10, 553-558.	2.6	11
47	Effects of ethanol and ipsapirone on the development of midline raphe glial cells and astrocytes. Alcohol, 2003, 29, 157-164.	1.7	10
48	Parkinson's disease – molecular mechanisms of disease. Drug Discovery Today Disease Mechanisms, 2004, 1, 399-405.	0.8	10
49	Multiplex protein-specific microscopy with ultraviolet surface excitation. Biomedical Optics Express, 2020, 11, 99.	2.9	10
50	Robust Tracing and Visualization of Heterogeneous Microvascular Networks. IEEE Transactions on Visualization and Computer Graphics, 2019, 25, 1760-1773.	4.4	8
51	In Utero Ethanol Exposure Increases Proenkephalin, a Precursor of a Neuropeptide That Is Inhibitory to Neuronal Growth. Alcoholism: Clinical and Experimental Research, 1999, 23, 1519-1527.	2.4	7
52	Elevated prostacyclin biosynthesis in mice impacts memory and anxiety-like behavior. Behavioural Brain Research, 2014, 258, 138-144.	2.2	7
53	Formaldehyde scavengers function as novel antigen retrieval agents. Scientific Reports, 2015, 5, 17322.	3.3	6
54	1â€Indanone and 1,3â€Indandione Derivatives as Ligands for Misfolded αâ€Synuclein Aggregates. ChemMedChem, 2022, 17, e202100611.	3.2	5

#	Article	IF	CITATIONS
55	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research, 2002, 56, 415-420.	2.9	4
56	Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and α-Synuclein, as Reported in ALS-PDC. Journal of Neuropathology and Experimental Neurology, 2021, 80, 286-288.	1.7	4
57	Biologic models of neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 173-188.	1.8	3
58	The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathologica, 2010, 119, 107-109.	7.7	3
59	7B2 chaperone knockout in APP model mice results in reduced plaque burden. Scientific Reports, 2018, 8, 9813.	3.3	3
60	Hyperspectral expansion microscopy. , 2017, , .		2
61	Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease. Current Enzyme Inhibition, 2013, 9, 46-54.	0.4	1
62	Segmenting Continuous but Sparsely-Labeled Structures in Super-Resolution Microscopy Using Perceptual Grouping. Lecture Notes in Computer Science, 2020, , 141-150.	1.3	1
63	Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2022, 16, 769347.	3.7	1
64	P4-422 Mechanism of neurofibrillary degeneration in a mouse model of tauopathy and progress towards identification of a therapeutic target. Neurobiology of Aging, 2004, 25, S594.	3.1	0
65	Editorial (Hot Topic Therapeutic Targets in Neurodegenerative Diseases). Current Enzyme Inhibition, 2013, 9, 1-2.	0.4	O
66	Microglia in the Alzheimers brain: a help or a hindrance?. AIMS Neuroscience, 2014, 1, 210-224.	2.3	0
67	Effects of Prostacyclin Signaling on Alzheimer's Disease Associated Pathologies. FASEB Journal, 2020, 34, 1-1.	0.5	o